. 2019 Sep 13;8(10):1372–1382. doi: 10.1530/EC-19-0317
This work is licensed under a Table 2.
Alcohol, glucose, insulin, C-peptide, glucagon, GIP, GLP-1 and FGF21.
| Administration form: | IGEI | IVEI | T test (P values) |
|---|---|---|---|
| Alcohol | |||
| Baseline (g/L) | 0 ± 0 | 0 ± 0 | |
| AUC0–240 min (g/L × min) | 251 ± 26 | 256 ± 30 | 0.38 |
| Peak plasma concentration (g/L) | 1.7 ± 0.3 | 1.8 ± 0.3 | 0.22 |
| Time to peak (min) | 38 ± 18 | 44 ± 4.3 | 0.24 |
| Glucose | |||
| Baseline (mmol/L) | 4.9 ± 0.3 | 4.9 ± 0.2 | 0.54 |
| AUC0-240 min (mmol/L × min) | 1177 ± 65 | 1127 ± 186 | 0.30 |
| Peak plasma concentration (mmol/L) | 5.3 ± 0.4 | 5.3 ± 0.3 | 0.34 |
| Time to peak (min) | 36 ± 53 | 54 ± 60 | 0.65 |
| Insulin | |||
| Baseline (pmol/L) | 53 ± 19 | 50 ± 18 | 0.67 |
| AUC0-240 min (pmol/L × min) | 12 ± 4.0 | 11 ± 3.7 | 0.18 |
| Nadir (pmol/L) | 36 ± 14 | 27 ± 12 | 0.04 |
| Time to nadir (min) | 86 ± 98 | 55 ± 40 | 0.23 |
| C-peptide | |||
| Baseline (pmol/L) | 321 ± 72 | 325 ± 87 | 0.82 |
| AUC0-240 min (pmol/L × min) | 69 ± 17 | 69 ± 21 | 0.95 |
| Nadir (pmol/L) | 242 ± 58 | 235 ± 74 | 0.77 |
| Time to nadir (min) | 151 ± 106 | 105 ± 91 | 0.08 |
| Insulin secretion rate | |||
| Baseline (pmol/kg/min) | 1.1 ± 0.3 | 1.1 ± 0.3 | 0.98 |
| AUC0-240 (pmol/kg/min × min) | 220 ± 56 | 219 ± 53 | 0.97 |
| Nadir (pmol/kg/min) | 0.6 ± 0.2 | 0.7 ± 0.2 | 0.94 |
| Time to nadir (min) | 93 ± 104 | 86 ± 89 | 0.88 |
| Insulin/glucose ratio | |||
| Baseline (pmol/mmol) | 11 ± 2.7 | 10 ± 2.5 | 0.60 |
| AUC0-240 (pmol/mmol × min) | 2504 ± 786 | 2153 ± 687 | 0.20 |
| Nadir (pmol/mmol) | 7.0 ± 2.5 | 5.3 ± 1.8 | 0.04 |
| Time to nadir (min) | 61 ± 88 | 44 ± 4.1 | 0.52 |
| Beta cells | |||
| Insulinogenic index | −29 ± 88 | −127 ± 152 | 0.05 |
| Glucagon | |||
| Baseline (pmol/L) | 6.0 ± 3.8 | 5.1 ± 1.7 | 0.45 |
| AUC0-240 min (pmol/L × min) | 1013 ± 678 | 1227 ± 552 | 0.20 |
| Nadir (pmol/L) | 2.2 ± 1.5 | 2.5 ± 1.6 | 0.37 |
| Time to nadir (min) | 41 ± 34 | 40 ± 27 | 0.91 |
| GIP | |||
| Baseline (pmol/L) | 17 ± 7.7 | 15 ± 4.6 | 0.14 |
| AUC0-240 min (pmol/L × min) | 2479 ± 1071 | 2496 ± 1240 | 0.96 |
| Peak plasma concentration (pmol/L) | 18 ± 5.6 | 18 ± 7.8 | 0.89 |
| Time to peak (min) | 70 ± 81 | 160 ± 73 | 0.01 |
| GLP-1 | |||
| Baseline (pmol/L) | 19 ± 7.9 | 21 ± 9.4 | 0.52 |
| AUC0-240 min (pmol/L × min) | 5093 ± 2103 | 4266 ± 1707 | 0.24 |
| Peak plasma concentration (pmol/L) | 30 ± 9.2 | 30 ± 7.9 | 0.67 |
| Time to peak (min) | 44 ± 34 | 65 ± 113 | 0.56 |
| FGF21 | |||
| Baseline (pg/mL) | 31 ± 35 | 30 ± 35 | 0.89 |
| AUC0-240 min (pg/mL × min) | 37,738 ± 27,855 | 32,592 ± 20,728 | 0.21 |
Differences between groups were compared with paired T test. Data are mean ± s.d.
AUC, area under the curve; FGF21; fibroblast growth factor 21; GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; IGEI, intragastric alcohol infusion; IVEI, intravenous alcohol infusion.